BDBM620868 (3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-chloro-1-(2,2-(R) or (S) difluorocyclopropyl)-1H- pyrazol-4-yl)amino)quinazolin- 7-yl)piperazin-1-yl)-4- methyltetrahydrofuran-3-ol::US20230303540, Example Ex-6.2::US20230303540, Example Ex-6.33::US20230303540, Example Ex-6.34::US20230303540, Example Ex-6.35

SMILES CC1(COCC1O)N1CCN(CC1)c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl

InChI Key InChIKey=QGXXZPMVJOVKPN-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 620868   

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.212nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 10.6nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 20.8nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent